CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

CVRx将报告2021年第二季度财务和经营业绩并主持电话会议

2021-07-22 13:00:27 BioSpace

本文共716个字,阅读需2分钟

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc.,  (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (833) 730-3980 for U.S. callers, or +1 (720) 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 1659235. To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations. The webcast replay will be available on the CVRx website for 12 months following completion of the call. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the US. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike Vallie Westwicke, an ICR Company ir@cvrx.com Media Contact: Lisa Murray Trevi Communications, Inc. 978.750.0333 / 617.835.0396 lisa@trevicomm.com
明尼阿波利斯,2021年7月21日(环球新闻)--CVRx,Inc.(“CVRx”)是一家商业化阶段的医疗设备公司,专注于为心血管疾病患者开发、制造和商业化创新和微创神经调节解决方案,今天宣布计划在2021年8月4日星期三收盘后发布第二季度财务和经营业绩。该公司将于美国东部时间当天下午5:30召开电话会议,审查其业绩。 若要通过电话收听电话会议,请在会议开始前约10分钟拨打(833)730-3980(美国来电者)或+1(720)405-2140(国际来电者),并参考会议代码1659235。要收听网上直播,请访问CVRx网站的投资者部分:ir.CVRx.com/investor-relations。网播重播将在呼叫完成后的12个月内在CVRx网站上提供。 关于CVRx公司。 CVRx专注于Barostim™的开发和商业化,这是FDA批准的第一项利用神经调节来改善心力衰竭患者症状的医疗技术。Barostim是一种可植入的装置,它向位于颈动脉壁的压力感受器传递电脉冲。压力感受器激活身体的压力反射,进而触发对心脏的自主反应。这种疗法旨在恢复自主神经系统的平衡,从而减少心力衰竭的症状。Barostim获得了FDA突破性设备的指定,并被FDA批准用于美国的心力衰竭患者。它还在欧洲经济区获得了心力衰竭和抵抗性高血压的CE标志。欲了解更多关于Barostim的信息,请访问www.cvrx.com。 投资者联系方式: 马克·克劳斯纳或迈克·瓦利 ICR公司Westwicke @cvrx.com 媒体联系: 丽莎·默里 特雷维通信公司。 978.750.0333/617.835.0396 @trevicomm.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文